Advanced search
Publication Cover
OncoImmunology Volume 7, 2018 - Issue 8
Submit an article Journal homepage
10,654
Views
16
CrossRef citations to date
0
Altmetric
Original Research

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM

Alice L. HungDepartment of Neurosurgery, Johns Hopkins Hospital, Baltimore, MD, USAView further author information
,
Russell MaxwellDepartment of Neurosurgery, Johns Hopkins Hospital, Baltimore, MD, USAView further author information
,
Debebe TheodrosDepartment of Neurosurgery, Johns Hopkins Hospital, Baltimore, MD, USA;Department of Oncology, Johns Hopkins Hospital, Baltimore, MD, USAView further author information
,
Zineb BelcaidDepartment of Neurosurgery, Johns Hopkins Hospital, Baltimore, MD, USAView further author information
,
Dimitrios MathiosDepartment of Neurosurgery, Johns Hopkins Hospital, Baltimore, MD, USAORCID Iconhttp://orcid.org/0000-0002-0792-6880View further author information
ORCID Icon,
Andrew S. LuksikDepartment of Neurosurgery, Johns Hopkins Hospital, Baltimore, MD, USAView further author information
,
Eileen KimDepartment of Neurosurgery, Johns Hopkins Hospital, Baltimore, MD, USAORCID Iconhttp://orcid.org/0000-0002-5469-4058View further author information
ORCID Icon,
Adela WuDepartment of Neurosurgery, Johns Hopkins Hospital, Baltimore, MD, USAView further author information
,
Yuanxuan XiaDepartment of Neurosurgery, Johns Hopkins Hospital, Baltimore, MD, USAORCID Iconhttp://orcid.org/0000-0001-6152-8392View further author information
ORCID Icon,
Tomas Garzon-MuvdiDepartment of Neurosurgery, Johns Hopkins Hospital, Baltimore, MD, USAView further author information
,
Christopher JacksonDepartment of Neurosurgery, Johns Hopkins Hospital, Baltimore, MD, USAView further author information
,
Xiaobu YeDepartment of Neurosurgery, Johns Hopkins Hospital, Baltimore, MD, USAView further author information
,
Betty TylerDepartment of Neurosurgery, Johns Hopkins Hospital, Baltimore, MD, USAView further author information
,
Mark SelbyBristol-Myers Squibb, New York, NY, USAORCID Iconhttp://orcid.org/0000-0002-3158-0947View further author information
ORCID Icon,
Alan KormanBristol-Myers Squibb, New York, NY, USAORCID Iconhttp://orcid.org/0000-0002-1142-8542View further author information
ORCID Icon,
Bryan BarnhartBristol-Myers Squibb, New York, NY, USAView further author information
,
Su-Myeong ParkWide River Institute of Immunology, Seoul National University College of Medicine, Hongcheon, KoreaView further author information
,
Je-In YounWide River Institute of Immunology, Seoul National University College of Medicine, Hongcheon, Korea;Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, KoreaView further author information
,
Tamrin ChowdhuryDepartment of Neurosurgery, Seoul National University College of Medicine, Seoul, KoreaView further author information
,
Chul-Kee ParkDepartment of Neurosurgery, Seoul National University College of Medicine, Seoul, KoreaView further author information
,
Henry BremDepartment of Neurosurgery, Johns Hopkins Hospital, Baltimore, MD, USAView further author information
,
Drew M. PardollDepartment of Oncology, Johns Hopkins Hospital, Baltimore, MD, USAView further author information
&
Michael LimDepartment of Neurosurgery, Johns Hopkins Hospital, Baltimore, MD, USACorrespondence[email protected]
View further author information
 show all
Article: e1466769 | Received 26 Feb 2018, Accepted 13 Apr 2018, Published online: 24 May 2018

References

  • Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–66. doi:10.1016/S1470-2045(09)70025-7. PMID:19269895.
  • Delgado-López PD, Corrales-García EM. Survival in glioblastoma: a review on the impact of treatment modalities. Clin Transl Oncol. 2016;18:1062–71. doi:10.1007/s12094-016-1497-x. PMID:26960561.
  • Feng E, Sui C, Wang T, Sun G. Temozolomide with or without radiotherapy in patients with newly diagnosed glioblastoma multiforme: A Meta-Analysis. Eur Neurol. 2017;77:201–10. doi:10.1159/000455842. PMID:28192785.
  • Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252–64. doi:10.1038/nrc3239. PMID:22437870.
  • Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8:467–77. doi:10.1038/nri2326. PMID:18500231.
  • Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011;29:235–71. doi:10.1146/annurev-immunol-031210-101324. PMID:21219185.
  • Hung AL, Garzon-Muvdi T, Lim M. Biomarkers and Immunotherapeutic Targets in Glioblastoma. World Neurosurg. 2017;102:494–506. doi:10.1016/j.wneu.2017.03.011. PMID:28300714.
  • Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167–75. doi:10.1200/JCO.2009.26.7609. PMID:20516446.
  • Hamid O, Robert C, Daud A, Hodi FS, Hwu W-J, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369:134–44. doi:10.1056/NEJMoa1305133. PMID:23724846.
  • Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16:257–65. doi:10.1016/S1470-2045(15)70054-9. PMID:25704439.
  • Wainwright DA, Chang AL, Dey M, Balyasnikova IV, Kim CK, Tobias A, Cheng YY, Kim JW, Qiao J, Zhang L, et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res. 2014;20:5290–301. doi:10.1158/1078-0432.CCR-14-0514. PMID:24691018.
  • Kim JE, Patel MA, Mangraviti A, Kim ES, Theodros D, Velarde E, Liu A, Sankey E, Tam A, Xu H, et al. Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas. Clin Cancer Res. 2016;23:124–36. doi:10.1158/1078-0432.CCR-15-1535. PMID:27358487.
  • Dougall WC, Kurtulus S, Smyth MJ, Anderson AC. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy. Immunol Rev. 2017;276:112–20. doi:10.1111/imr.12518. PMID:28258695.
  • Manieri NA, Chiang EY, Grogan JL. TIGIT: A Key Inhibitor of the Cancer Immunity Cycle. Trends Immunol. 2017;38:20–8. doi:10.1016/j.it.2016.10.002. PMID:27793572.
  • Liu X, Hou M, Liu Y. TIGIT, a novel therapeutic target for tumor immunotherapy. Immunol Invest. 2017;46:172–82. doi:10.1080/08820139.2016.1237524. PMID:27819527.
  • Yu X, Harden K, C Gonzalez L, Francesco M, Chiang E, Irving B, Tom I, Ivelja S, Refino CJ, Clark H, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 2009;10:48–57. doi:10.1038/ni.1674. PMID:19011627.
  • Lozano E, Dominguez-Villar M, Kuchroo V, Hafler DA. The TIGIT/CD226 axis regulates human T cell function. J Immunol. 2012;188:3869–75. doi:10.4049/jimmunol.1103627. PMID:22427644.
  • Stanietsky N, Rovis TL, Glasner A, Seidel E, Tsukerman P, Yamin R, Enk J, Jonjic S, Mandelboim O. Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR. Eur J Immunol. 2013;43:2138–50. doi:10.1002/eji.201243072. PMID:23677581.
  • Chauvin J-M, Pagliano O, Fourcade J, Sun Z, Wang H, Sander C, Kirkwood JM, Chen TT, Maurer M, Korman AJ, et al. TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients. J Clin Invest. 2015;125:2046–58. doi:10.1172/JCI80445. PMID:25866972.
  • Kurtulus S, Sakuishi K, Ngiow S-F, Joller N, Tan DJ, Teng MWL, Smyth MJ, Kuchroo VK, Anderson AC. TIGIT predominantly regulates the immune response via regulatory T cells. J Clin Invest. 2015;125:4053–62. doi:10.1172/JCI81187. PMID:26413872.
  • Johnston RJ, Comps-Agrar L, Hackney J, Yu X, Huseni M, Yang Y, Park S, Javinal V, Chiu H, Irving B, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8 + T cell effector function. Cancer Cell. 2014;26:923–37. doi:10.1016/j.ccell.2014.10.018. PMID:25465800.
  • Kong Y, Zhu L, Schell TD, Zhang J, Claxton DF, Ehmann WC, Rybka WB, George MR, Zeng H, Zheng H. T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell exhaustion and poor clinical outcome in AML patients. Clin Cancer Res. 2016;22:3057–66. doi:10.1158/1078-0432.CCR-15-2626. PMID:26763253.
  • Sloan KE, Eustace BK, Stewart JK, Zehetmeier C, Torella C, Simeone M, Roy JE, Unger C, Louis DN, Ilag LL, et al. CD155/PVR plays a key role in cell motility during tumor cell invasion and migration. BMC Cancer 2004;4:73. doi:10.1186/1471-2407-4-73. PMID:15471548.
  • Woroniecka K, Chongsathidkiet P, Rhodin KE, Kemeny HR, Dechant CA, Farber SH, Elsamadicy AA, Cui X, Koyama S, Jackson CC, et al. T Cell exhaustion signatures vary with tumor type and are severe in glioblastoma. Clin Cancer Res. 2018; clincanres.1846.2017. doi:10.1158/1078-0432.CCR-17-1846. PMID:29437767. [ahead of print].
  • Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ, Asahina H, et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016;7:10501. doi:10.1038/ncomms10501. PMID:26883990.
  • Belcaid Z, Phallen JA, Zeng J, See AP, Mathios D, Gottschalk C, Nicholas S, Kellett M, Ruzevick J, Jackson C, et al. Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model. PLoS One 2014;9:e101764. doi:10.1371/journal.pone.0101764. PMID:25013914.
  • Chaudhary B, Elkord E. Regulatory T Cells in the tumor microenvironment and cancer progression: Role and therapeutic targeting. Vaccines 2016;4. doi:10.3390/vaccines4030028. PMID:27509527.
  • Facciabene A, Motz GT, Coukos G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res. 2012;72:2162–71. doi:10.1158/0008-5472.CAN-11-3687. PMID:22549946.
  • Takeuchi Y, Nishikawa H. Roles of regulatory T cells in cancer immunity. Int Immunol. 2016;28:401–9. doi:10.1093/intimm/dxw025. PMID:27160722.
  • Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, Krzysiek R, Knutson KL, Daniel B, Zimmermann MC, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med. 2003;9:562–7. doi:10.1038/nm863. PMID:12704383.
  • Aspord C, Pedroza-Gonzalez A, Gallegos M, Tindle S, Burton EC, Su D, Marches F, Banchereau J, Palucka AK. Breast cancer instructs dendritic cells to prime interleukin 13–secreting CD4 + T cells that facilitate tumor development. J Exp Med. 2007;204:1037–47. doi:10.1084/jem.20061120. PMID:17438063.
  • Norian LA, Rodriguez PC, O'Mara LA, Zabaleta J, Ochoa AC, Cella M, Allen PM. Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism. Cancer Res. 2009;69:3086–94. doi:10.1158/0008-5472.CAN-08-2826. PMID:19293186.
  • Kumar R, de Mooij T, Peterson TE, Kaptzan T, Johnson AJ, Daniels DJ, Parney IF. Modulating glioma-mediated myeloid-derived suppressor cell development with sulforaphane. PLoS One 2017;12:e0179012. doi:10.1371/journal.pone.0179012. PMID:28666020.
  • Chae M, Peterson TE, Balgeman A, Chen S, Zhang L, Renner DN, Johnson AJ, Parney IF. Increasing glioma-associated monocytes leads to increased intratumoral and systemic myeloid-derived suppressor cells in a murine model. Neuro Oncol. 2015;17:978–91. doi:10.1093/neuonc/nou343. PMID:25537019.
  • Raychaudhuri B, Rayman P, Huang P, Grabowski M, Hambardzumyan D, Finke JH, Vogelbaum MA. Myeloid derived suppressor cell infiltration of murine and human gliomas is associated with reduction of tumor infiltrating lymphocytes. J Neurooncol. 2015;122:293–301. doi:10.1007/s11060-015-1720-6. PMID:25579983.
  • Leite KRM, Reis ST, Junior JP, Zerati M, Gomes D de O, Camara-Lopes LH, Srougi M. PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis. Diagn Pathol. 2015;10:189. doi:10.1186/s13000-015-0414-x. PMID:26470780.
  • Qin T, Zeng Y, Qin G, Xu F, Lu J, Fang W, Xue C, Zhan J, Zhang X, Zheng Q, et al. High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer. Oncotarget. 2015;6:33972–81. doi:10.18632/oncotarget.5583. PMID:26378017.
  • Zhu H, Qin H, Huang Z, Li S, Zhu X, He J, Yang J, Yu X, Yi X. Clinical significance of programmed death ligand-1 (PD-L1) in colorectal serrated adenocarcinoma. Int J Clin Exp Pathol. 2015;8:9351–9. PMID:26464688.
  • Nduom EK, Wei J, Yaghi NK, Huang N, Kong L-Y, Gabrusiewicz K, Ling X, Zhou S, Ivan C, Chen JQ, et al. PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol. 2016;18:195–205. doi:10.1093/neuonc/nov172. PMID:26323609.
  • Gao X, Zhu Y, Li G, Huang H, Zhang G, Wang F, Sun J, Yang Q, Zhang X, Lu B, et al. TIM-3 Expression Characterizes Regulatory T Cells in Tumor Tissues and Is Associated with Lung Cancer Progression. PLoS One 2012;7:e30676. doi:10.1371/journal.pone.0030676. PMID:22363469.
  • Li F-J, Zhang Y, Jin G-X, Yao L, Wu D-Q. Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8+ T cell in HCC patients. Immunol Lett. 2013;150:116–22. doi:10.1016/j.imlet.2012.12.004. PMID:23261718.
  • Salvi S, Fontana V, Boccardo S, Merlo DF, Margallo E, Laurent S, Morabito A, Rijavec E, Dal Bello MG, Mora M, et al. Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer. Cancer Immunol Immunother 2012;61:1463–72. doi:10.1007/s00262-012-1211-y. PMID:22318401.
  • Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J, Durham N, Meyer C, Harris TJ, Albesiano E, et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys. 2013;86:343–9. doi:10.1016/j.ijrobp.2012.12.025. PMID:23462419.
  • Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54. doi:10.1056/NEJMoa1200690. PMID:22658127.
  • Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271:1734–6. doi:10.1126/science.271.5256.1734. PMID:8596936.
  • Camacho LH, Antonia S, Sosman J, Kirkwood JM, Gajewski TF, Redman B, Pavlov D, Bulanhagui C, Bozon VA, Gomez-Navarro J, et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol. 2009;27:1075–81. doi:10.1200/JCO.2008.19.2435. PMID:19139427.
  • Fecci PE, Ochiai H, Mitchell DA, Grossi PM, Sweeney AE, Archer GE, Cummings T, Allison JP, Bigner DD, Sampson JH. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res. 2007;13:2158–67. doi:10.1158/1078-0432.CCR-06-2070. PMID:17404100.
  • Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010;207:2187–94. doi:10.1084/jem.20100643. PMID:20819927.
  • Lieberman F.. Glioblastoma update: molecular biology, diagnosis, treatment, response assessment, and translational clinical trials. F1000Research 2017;6:1892. doi:10.12688/f1000research.11493.1. PMID:29263783.
  • Böker DK, Kalff R, Gullotta F, Weekes-Seifert S, Möhrer U. Mononuclear infiltrates in human intracranial tumors as a prognostic factor. Influence of preoperative steroid treatment. I. Glioblastoma. Clin Neuropathol 1984;3:143–7. PMID:6478676.
  • Brooks WH, Markesbery WR, Gupta GD, Roszman TL. Relationship of lymphocyte invasion and survival of brain tumor patients. Ann Neurol. 1978;4:219–24. doi:10.1002/ana.410040305. PMID:718133.
  • Palma L, Di Lorenzo N, Guidetti B. Lymphocytic infiltrates in primary glioblastomas and recidivous gliomas. J Neurosurg. 1978;49:854–61. doi:10.3171/jns.1978.49.6.0854. PMID:731302.
  • Slifka MK, Whitton JL. Phenotypic Markers Distinguished by Their Cytokine Profiles and T Cells Can Be + Activated and Memory CD8 Activated and Memory CD8 □ T Cells Can Be Distinguished by Their Cytokine Profiles and Phenotypic Markers. J Immunol by guest January 2000;164:208–16. doi:10.4049/jimmunol.164.1.208.
  • Ding Z-C, Huang L, Blazar BR, Yagita H, Mellor AL, Munn DH, Zhou G. Polyfunctional CD4+ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy. Blood 2012;120:2229–39. doi:10.1182/blood-2011-12-398321. PMID:22859605.
  • Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975;72:3666–70. doi:10.1073/pnas.72.9.3666. PMID:1103152.
  • Sato N, Fukuda K, Nariuchi H, Sagara N. Tumor necrosis factor inhibiting angiogenesis in vitro. J Natl Cancer Inst. 1987;79:1383–91. PMID:2447319.
  • Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res. 1987;47:5155–61. PMID:2441862.
  • Saiki I, Sato K, Yoo YC, Murata J, Yoneda J, Kiso M, Hasegawa A, Azuma I. Inhibition of tumor-induced angiogenesis by the administration of recombinant interferon-gamma followed by a synthetic lipid-A subunit analogue (GLA-60). Int J cancer. 1992;51:641–5. doi:10.1002/ijc.2910510422. PMID:1376302.
  • Saleh M, Jonas NK, Wiegmans A, Stylli SS. The treatment of established intracranial tumors by in situ retroviral IFN-γ transfer. Gene Ther. 2000;7:1715–24. doi:10.1038/sj.gt.3301273. PMID:11083492.
  • Beissert S, Schwarz A, Schwarz T. Regulatory T cells. J Invest Dermatol. 2006;126:15–24. doi:10.1038/sj.jid.5700004. PMID:16417213.
  • Jacobs JFM, Idema AJ, Bol KF, Nierkens S, Grauer OM, Wesseling P, Grotenhuis JA, Hoogerbrugge PM, de Vries IJM, Adema GJ. Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Neuro Oncol. 2009;11:394–402. doi:10.1215/15228517-2008-104. PMID:19028999.
  • Sonabend AM, Rolle CE, Lesniak MS. The role of regulatory T cells in malignant glioma. Anticancer Res. 28:1143–50. PMID:18505050.
  • Okita Y, Tanaka H, Ohira M, Muguruma K, Kubo N, Watanabe M, Fukushima W, Hirakawa K. Role of tumor-infiltrating CD11b+ antigen-presenting cells in the progression of gastric cancer. J Surg Res. 2014;186:192–200. doi:10.1016/j.jss.2013.08.024. PMID:24120241.
  • Lin A, Schildknecht A, Nguyen LT, Ohashi PS. Dendritic cells integrate signals from the tumor microenvironment to modulate immunity and tumor growth. Immunol Lett. 2010;127:77–84. doi:10.1016/j.imlet.2009.09.003. PMID:19778555.
  • Nakahara T, Oba J, Shimomura C, Kido-Nakahara M, Furue M. Early Tumor-Infiltrating Dendritic Cells Change their Characteristics Drastically in Association with Murine Melanoma Progression. J Invest Dermatol. 2016;136:146–53. doi:10.1038/JID.2015.359. PMID:26763434.
  • Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1-. doi:10.1126/scisignal.2004088. PMID:23550210.
  • Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401–4. doi:10.1158/2159-8290.CD-12-0095. PMID:22588877.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.